absolute counting beads (Invitrogen, Carlsbad, CA) were used for cell count. For analysis of apoptosis, cells were stained with FITC-conjugated Annexin V (BioLegend, San Diego, CA) in Annexin binding buffer (BioLegend) . Ki-67 and Foxp3 was stained after permeabilization using Foxp3 staining buffer (Thermo Fisher Scientific, Waltham, MA) to evaluate donor T cell proliferation and expansion of donor regulatory T cells, respectively. To evaluate cytokine production, cells were stimulated by 50 ng/mL of phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 1 µg/mL of ionomycin (Sigma-Aldrich) for 6 h at 37ºC, and Golgi-stop (BD Pharmingen) was added for the last 5 h. After staining surface markers, cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA), followed by interferon-g (IFN-g) staining. Serum levels of IFN-g were measured using a BD Cytometric Bead Array kit (BD Biosciences). Labeled cells were analyzed using a FACS CantoII (BD Biosciences) and FlowJo software (TreeStar, Ashland, OR).
Histology. Tissue samples were fixed with 4% paraformaldehyde overnight, embedded in paraffin, and stained with hematoxylin and eosin (H&E). Images were acquired at room temperature using a BX50 microscopy (Olympus, Tokyo, Japan) with a 10×/0.30 NA, 20×/0.45 NA, or 40×/0.95 NA objective lens. We also made the section of rolled skin samples to count the number of hair follicles. The number of hair follicles standardized with sample length (cm) was compared among mice.
Immunofluorescent study. Entire back skin was rolled and incubated with 4% paraformaldehyde overnight.
For antigens retrieval, sections of rolled skin were heated in Target Retrieval Solution pH 9 (Dako Japan, Kyoto, Japan) at 105 °C for 20 min. The sections were then treated with blocking reagents containing 10% goat serum for 30 min, followed by incubation with primary antibodies listed in Table S1 at 4 °C overnight.
The primary Abs were visualized by incubating with Alexa Fluor 488 or 555 conjugated goat anti-chicken polyclonal Abs or goat anti-rabbit polyclonal Abs for 1 h and nuclei were stained with DAPI. Images were acquired with a Fluoview FV1000 confocal microscopy (Olympus). Images were processed with Adobe Photoshop CC 2017. 
Figure S3. Topical ruxolitinib promotes wound healing made on day +28 after allogeneic SCT
B6 mice were transplanted as in Figure 1 . Wounding was performed on day +28. Wound areas were measured daily for 7 days after wounding (n=6-8 /group). Data from 2 independent experiments are combined and shown as the mean ± SEM. **P<0.01. 
Figure S5. Systemic administration of ruxolitinib, not corticosteroid protects HFSCs against GVHD
Lethally irradiated B6-Lgr5 EGFP-cre/ER were transplanted with 20 × 10 6 G-CSF mobilized splenocytes from allogeneic (Allo) BALB/c mice on day 0. Ctrl or ruxolitinib ointment was administered onto shaved back skin from day +1. For systemic therapy, 10 mg/kg prednisolone (PSL, once daily) or 30 mg/kg ruxolitinib (Ruxo, twice daily) were orally administered from day +1 after SCT. A group of recipients were treated with ruxolitinib ointment in combination with systemic ruxolitinib. Numbers of Lgr5 + HFSCs (A) and donor T cells in the PSL-treated skin (B) on day +14 from two independent experiments were combined and shown as the mean ± SEM (n=5-6 /group). *P<0.05, **P<0.01, ns: not significant. Mann-Whitney U testes or One-way ANOVA followed by Tukey's post-test was used to compare the data.
Data represent the mean ± SEM from 2-3 independent experiments. *P<0.05, **P<0.01, ***P<0.005, ns: not significant.
Figure S8. Oral administration of ruxolitinib protects CK15 + epidermal stem cells in RLPs after allogeneic SCT.
Lethally irradiated B6 mice were transplanted as in Fig. S3 . Vehicle (Ctrl) or ruxolitinib (Ruxo) at a dose of 60 mg/kg/day was orally given twice daily from day +1 after SCT. Immunofluorescent staining of CK15
(red) and DAPI (blue) in lingual sections harvested on day +9 after SCT. Magnification, 40×. Scale bar, 25
µm. Figure S9 . Therapeutic administration of systemic ruxolitinib ameliorates established systemic acute
GVHD.
Lethally irradiated B6 mice were transplanted as in Figure 1 . Ruxolitinib or vehicle were orally administered twice daily from day +9 after SCT. Survival rate (A) and clinical GVHD scores (B, the mean ± SEM) from two independent experiments were combined (n=8-10 /group). *P<0.05, **P<0.01. 
